Furthermore, the NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) reduced expression of integrin β1 and α2 chains and was effective, both in vitro and in vivo, in preventing PM formation from gastric cancer [48]. Here, NFKB1 is linked to gastric cancer.